N-Acetylation and hydroxylation polymorphisms in type II diabetics with microvascular disturbances

European Journal of Clinical Pharmacology

Volumn 51, Issue 6, 1997, Pages 431-435

  Gawronska Szklarz B ^a   Gornik W ^a   Pawlik, A ^a   Kunicki, P ^b   Wojcicki J ^a   Sitkiewicz, D ^b   Sych, Z ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF CARDIOLOGY   (Poland)

Author keywords

Debrisoquine; Genetic polymorphism; Hydroxylation; Microvascular disturbances; n Acetylation; Type II diabetics

Indexed keywords

CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; SULFADIMIDINE;

ACETYLATION; ACETYLATOR PHENOTYPE; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; FEMALE; GENETIC POLYMORPHISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROXYLATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL;

ACETYLATION; ADULT; AGED; DEBRISOQUIN; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; GENE FREQUENCY; HUMANS; HYDROXYLATION; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; SULFAMETHAZINE;

EID: 0030750191     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050226     Document Type: Article

References (40)

1. Evans DAP (1984) Survey of the human acetylator polymorphism in spontaneous disorders. J Med Genet 21: 243-253
2. Evans DAP (1989) N-Acetyltransferase. Pharmacol Ther 42: 157-234
3. Siegmund W, Fengler J, Franke G, Zschiesche M, Eike D, Eike E, Meisel P, Wukow R (1991) N-Acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert's syndrome. Br J Clin Pharmacol 32: 467-472
4. Law H, Hetzel M, Idle J (1989) Debrisoquine metabolism and genetic predisposition to lung cancer. Br J Cancer 59: 686-687
5. Fleming G, Persad R, Kaisary A, Smith P, Adedoyin A, Porter J, Wilkinson G, Branch R (1994) Low activity of dapsone N-hydroxylation as a susceptibility risk factor in aggressive bladder cancer. Pharmacogenetics 4: 199-207
6. Ayesh R, Idle J, Ritchie J, Crothers M, Hetzel M (1984) Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 312: 169-170
7. Aquindez J, Martinez C, Ladero J, Ledesma C, Ramos J, Martin R, Rodriquez A, Jara C, Benitez J (1994) Debrisoquine oxidation genotype and susceptibility to lung cancer. Clin Pharmacol Ther 55: 10-14
8. Smith C, Gough A, Leigh P, Summers B, Harding A, Maranganore D, Sturman S, Schapira A, Williams A, Spurr N, Wolf C (1992) Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 339: 1375-1377
9. Stewart LL, Field LL, Ross S, McArthur RG (1993) Genetic risk factors in diabetic retinopathy. Diabetologia 36: 1293-1298
10. Mattila MJ, Tiitinen H (1967) The rate of isoniazid inactvation in Finnish diabetic and non-diabetic patients. Ann Med Exp Biol Fenn 45: 423-427
11. Shenfield GM, MeCann VJ, Tjokresetio R (1982) Acetylator status and diabetic neuropathy. Diabetologia 22: 441-144
12. Burrows A, Hockaday TD, Mann JI, Taylor JG (1978) Diabetic dimorphism according to acetylator status. BMJ 1: 208-210
13. Stryjek-Kamińska D, Malczewaki B, Kopeć A, Rowińska-Marcińska K (1988) Acetylator phenotypes in diabetes mellitus. Acta Diabetol Lat 25: 41-48
14. McLaren EH, Burden AC, Moorhead PJ (1977) Acetylator phenotype in diabetic neuropathy. BMJ 2: 291-293
15. Miarka J, Straszecka J, Jonderko G, Lachowicz B (1990) Acetylation phenotype as a risk factor of diabetic neuropathy (in Polish) Przegl Lek 4: 385-388
16. Bodansky MJ, Drury PL, Cudworth AG, Evans DAP (1981) Acetylation phenotypes and type I (insulin-dependent) diabetics with microvascular disease. Diabetes 30: 907-910
17. Ladero JM, Arrojo A, de Salamanca RE, Gomez M, Cano F, Alfons M (1982) Hepatic acetylator phenotype in diabetes mellitus. Ann Clin Res 14: 187-189
18. Evans DAP, Paterson S, Francisco P, Alvarez G (1985) The acetylator phenotypes of Saudi Arabian diabetics. J Med Genet 22: 479-483
19. Kallio J, Huupponen R, Viikari J (1990) Debrisoquine hydroxylation polymorphism in diabetic patients. Diabetes Res 15: 125-129
20. Christy M, Green A, Christan B, Kromann H, Nerup J, Platz P, Thomsen M, Ryder LP, Svejgaard A (1979) Studies on the HLA system and insulin dependent diabetes mellitus. Diabetes Care 2: 209-214
21. Cudworth AG (1980) Current concepts of aetiology: type I (insulin-dependent) diabetes mellitus. In Bellingham AG (ed) Advanced medicine, 16th edn. Pitman Medical, Tunbridge Wells, pp 123-135
22. Pyke DA, Tattersall RB (1973) Diabetic retinopathy in identical twins. Diabetes 22: 613-618
23. Evans DAP (1969) An improved and simplified method of detecting the acetylation phenotype. J Med Gent 16: 405-407
24. Varley H (1954) Practical clinical biochemistry. Heinemann, London, pp 634-636
25. Rieder J (1972) Quantitative determination of the bacteriostatically active fraction of sulfonamides and the sum of their inactive metabolites in the body fluids. Chemotherapy 17: 1-21
26. Kunicki PK, Sitkiewicz D, Pawlik A, Bielicka-Sulzyc V, Borowiecka E, Gawrońska-Szklarz B, Sterna R, Matsumoto H, Radziwoń-Zaleska M (1995) Debrisoquine hydroxylation in a Polish population. Eur J Clin Pharmacol 41: 503-505
27. Evans DAP, Maghoub A, Sloan TP, Idle IR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17: 102-105
28. Johansson I, Lundqvist E, Bertilsson L, Dahl M-L, Sjoqvist F, Ingelman-Sundberg M (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 90: 11825-11829
29. Mura C, Panserat S, Vincent-Viry M, Galteau MM, Jacqz-Aigrain E, Krishnamoorthy R (1993) DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolizers. Hum Genet 92: 367-372
30. Johanson NL, Leone FC (1977) Statistics and experimental design in engineering and the physical sciences. John Wiles & Sons, New York, pp 286-288
31. Orzechowska-Juzwenko K, Milejski P, Patkowski J, Nittner-Marszalska M, Malolepszy J (1990) Acetylator phenotype in patients with allergic disease and its clinical significance. Int J Clin Pharmacol Ther Toxicol 28: 420-425
32. Skrȩtkowicz J, Mazurowa A, Orszulak D (1981) Acetylation phenotype in a group of population from the Lódź region (in Polish) Pol Tyg Lek 3: 89-91
33. Evans DAP (1992) A-Acetyltransferase. In: Kalow W (ed) Pharmacogenetics of drug metabolism. Pergamon Press, New York, 95-178
34. Mrozikiewicz PM, Drakoulis N, Roots I (1994) Polymorphic arylamine N-acetyltransferase (NAT2) genes in children with insulin-dependent diabetes mellitus. Clin Pharmacol Ther 56: 626-634
35. Lindsay RM, Baty ID (1990) The effect of streptozotocin-induced diabetes on the in vivo acetylation capacity and the in vitro blood N-acetyltransferase activity of the adult male Sprague-Dawley rat. Biochem Pharmacol 39: 1193-1197
36. Lindsay RM, Baird ID (1991) The effect of diabetes on the in vivo acetylation capacity of the spontaneously diabetic, insulin-dependent BB/Edinburgh Wistar rat. Biochem Pharmacol 41: 425-430
37. Stroev EA, Belkina ZV (1989) Effect of antidiabetic preparations on the processes of xenobiotic metabolism. Farmakol Toksikol 52: 74-77
38. Suhardjono D, Boutagy J, Shenfield GM (1986) The effect of glucose on acetylation status. Br J Clin Pharmacol 22: 401-408
39. Hickman S, Sime E (1991) N-Acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. Biochem Pharmacol 42: 1007-1014
40. Neugebauer S, Baba T, Watanabe T, Ishizaki T, Kurokawa K (1994) The N-acetyltransferase (NAT) gene: an early risk marker for diabetic nephropathy in Japanese type II diabetic patients? Diabet Med 11: 783-788